December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

185.61 -2.11 (-1.12%)
Streaming Delayed Price Updated: 12:41 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 Next >
News headline image
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
From AstraZeneca
Via Business Wire
News headline image
This Low-Cost ETF Holds Almost 8,800 Stocks Across Both Developed and Emerging Markets. Here's Why It's a Compelling Long-Term Core Holding ↗
If you're looking for diversification and value, here's a good ETF to check out. 
Via The Motley Fool
Topics ETFs
News headline image
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗
Via MarketBeat
News headline image
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
From AstraZeneca
Via Business Wire
AstraZeneca (NYSE:AZN) Passes the Caviar Cruise Quality Screen with Strong Profitability and Growth ↗
Via Chartmill
News headline image
AstraZeneca results: Q1 2026
From AstraZeneca
Via Business Wire
News headline image
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
From AstraZeneca
Via Business Wire
News headline image
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
From AstraZeneca
Via Business Wire
News headline image
Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
This pharma stock is cheap for a reason. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
From AstraZeneca
Via Business Wire
News headline image
Pictet Loads Up MercadoLibre With 3,500 Shares Worth $6.8 Million ↗
MercadoLibre powers e-commerce, payments, and logistics for millions in Latin America with its integrated digital platform. 
Via The Motley Fool
News headline image
Could AbbVie Crash Lilly's Weight‑Loss Party? ↗
AbbVie is making progress in this market, but it is still far behind the leader. 
Via The Motley Fool
News headline image
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL... 
Via MarketMinute
Topics Economy
News headline image
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total... 
Via MarketMinute
Topics Bonds
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff... 
Via MarketMinute
Topics Economy Government Lawsuit
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
From AstraZeneca
Via Business Wire
News headline image
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF... 
Via MarketMinute
Topics ETFs Intellectual Property Stocks
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
From AstraZeneca
Via Business Wire
News headline image
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush
As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Could This International ETF Be One of the Best Investments of 2026? ↗
International stocks look attractively valued in an expensive market environment. 
Via The Motley Fool
Topics ETFs
News headline image
The 'Sentiment Trap': Why Beating Earnings Is No Longer Enough in the Age of AI Sentiment Analysis
In the high-stakes theater of corporate earnings calls, a "beat" on the bottom line used to be a guaranteed ticket to a stock price rally. However, as we move through the first quarter of 2026, a new... 
Via MarketMinute
Topics Artificial Intelligence Earnings Regulatory Compliance
News headline image
The Billion-Dollar Divide: How "Megadeals" Are Defining a K-Shaped M&A Market in 2026
The opening months of 2026 have revealed a startling paradox in the global financial landscape: while the sheer number of corporate marriages is dwindling, the price tags on the few remaining... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering... 
Via Finterra
Topics Economy Intellectual Property Lawsuit
News headline image
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
From AstraZeneca
Via Business Wire
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
News headline image
The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026
As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.